Peter Harris
Staff Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Year:
2026
STables 1-9: STable 1: H&N Panel regions. STable 2: Covariate analysis of cohort. STables 3 & 4: COX regression analysis. STables 5-7: Cohort Characteristics. STable 8: Lymph sequencing metrics. STable 9: Tumor mutations by patient.
Year:
2026
Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Year:
2025
Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.
Year:
2025
Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.
Year:
2025
Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.
Year:
2025
Supplementary Figure S4. Summary of alterations in biologically relevant pathways found in pre-ARSI plasma cell-free DNA of 63 metastatic castration-resistant prostate cancer patients. ARSI, androgen receptor-signaling inhibitors.
Year:
2025
Supplementary Figure S9. Cell-free DNA methylation analysis of differentially accessible transcription factor binding sites. The box and whisker plots summarize methylation levels in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients after z-score transformation of the 10,000 TF binding sites corresponding to each of the top 20 TFs that are (A) most accessible and (B) least accessible in cfDNA from AR /enhancer altered lethal high-risk mCRPC patients. p values were calculated by the Mann-Whitney U test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (17)
Oliver Sartor
Tulane University School of Medicine
Heath Skinner
Professor & Chair
University of Pittsburgh
Sean Park
Professor
Mayo Clinic Rochester
Jin Zhang
Associate Professor
Washington University in St. Louis
Jeffrey Szymanski
Assistant Professor
Mayo Clinic Minnesota
Jace Webster
Full Specialist
University of California, San Francisco
Aadel A. Chaudhuri
Washington University School of Medicine
Jacob Orme
Assistant Professor
Mayo Clinic
Matthew E. Spector
University of Pittsburgh Medical Center
Pradeep Chauhan
Assistant Professor
Mayo Clinic
Sidharth V. Puram
Washington University School of Medicine
Fabrice Lucien
Assistant Professor
Mayo Clinic Minnesota
Jose P. Zevallos
University of Pittsburgh Medical Center
Russell K. Pachynski
Washington University School of Medicine
Robert Ferris
UPMC Endowed Professor
University of Pittsburgh School of Medicine
Christopher A Maher
Washington University in St. Louis
Wade Thorstad
Professor
Washington University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.